Morepen Laboratories Reports Strong Q2 Growth and Legal Relief

Revenue reached Rs 746.50 crore, while net profit soared to Rs 88.89 crore.

Reader Takeaway: Robust top-line growth is bolstered by the removal of a major Rs 317.37 crore contingent liability risk.

What just happened

Morepen Laboratories has posted a strong financial performance for the quarter ended September 30, 2026. The company recorded a consolidated revenue of Rs 746.50 crore, representing a sharp increase from Rs 411.58 crore reported in the same quarter last year. Profit after minority interest jumped to Rs 88.89 crore, compared to Rs 40.87 crore in Q2 FY26. Additionally, the company successfully paid out a dividend of Rs 0.20 per share on October 13, 2026.

Why this matters

Beyond the earnings growth, the company achieved a significant regulatory win. On October 14, 2026, the Himachal Pradesh High Court quashed a Show Cause Notice from the Central GST & Central Excise department seeking Rs 117.94 crore. This legal development results in the removal of a Rs 317.37 crore contingent liability, which previously accounted for the recovery amount, interest, and potential penalties.

The backstory

This contingent liability had been a disclosed risk factor for investors in previous filings. The resolution of this long-standing tax matter provides clarity on the company's financial obligations and improves the overall quality of its balance sheet.

Context metrics

For the first half of FY27 (H1), Morepen reported revenue of Rs 1,316.63 crore and a net profit of Rs 145.29 crore, demonstrating consistent momentum compared to the H1 FY26 revenue of Rs 836.81 crore and profit of Rs 51.62 crore.

What to track next

Investors should monitor how the company allocates capital now that the uncertainty regarding the major contingent liability has been resolved. The focus will remain on sustaining the current growth margins in upcoming quarters.